Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:The_Fall
|
| gptkbp:appointed_by |
Emergency situations
Placing under the tongue |
| gptkbp:benefits |
Avoids first-pass metabolism
|
| gptkbp:can_be |
High-fat meals
|
| gptkbp:can_be_used_with |
Other routes of administration
|
| gptkbp:caused_by |
Dizziness
Headache Dry mouth |
| gptkbp:dissolved |
Saliva
|
| gptkbp:formulation |
Solid dosage form
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sub-Lingual Tablet
|
| gptkbp:ingredients |
gptkb:Buprenorphine
gptkb:Fentanyl Nitroglycerin Rapidly dissolving agents |
| gptkbp:interacts_with |
Alcohol
CNS depressants |
| gptkbp:is_available_in |
Various strengths
Flavored options |
| gptkbp:is_considered |
A convenient dosage form
A first-line treatment for all conditions |
| gptkbp:is_effective_against |
Rapid relief of symptoms
|
| gptkbp:is_expected_to |
As directed by a healthcare provider
|
| gptkbp:is_often_compared_to |
Intravenous administration
Transdermal patches |
| gptkbp:is_part_of |
Sub-lingual drug delivery system
|
| gptkbp:is_subject_to |
Regulatory approval
|
| gptkbp:is_used_by |
Patients with acute angina
Patients with opioid dependence |
| gptkbp:is_used_for |
Anxiety management
Hormonal replacement therapy Nausea control Rapid absorption of medication |
| gptkbp:is_used_in |
Certain medications
|
| gptkbp:manufacturer |
Various pharmaceutical companies
|
| gptkbp:packaging |
Blister pack
|
| gptkbp:requires |
gptkb:battle
Patient compliance Monitoring of side effects |
| gptkbp:security_features |
Adults when used correctly
|
| gptkbp:shelf_life |
Typically 1-2 years
|
| gptkbp:storage |
Cool, dry place
|
| gptkbp:suitable_for |
Patients with swallowing difficulties
Children without medical advice Oral tablets for certain conditions |
| gptkbp:used_in |
Pain management
Hormonal therapy Cardiac conditions |